title: [Combined therapy of pulmonary tuberculosis by using recombinant interleukins].
abstract: The use of roncoleukin in the combined therapy in patients with pulmonary tuberculosis caused by drug-resistant Mycobacterium tuberculosis (MBT) led to better immunological parameters and therapeutic efficiency: by month 3 of therapy, there was abacillation (69.2% versus 33.3% in the control) (p < 0.05), decay cavities closed by months 6 to 7 (59.0% versus 23.1%). The immunotropic effect of betaleukin on chemotherapy promoted accelerated involution of a specific process with the least pronounced residual changes in the lung tissue; by the end of an inpatient stage of therapy, the proportion of patients with minor residual changes (Type I and Type II) was 72.5% in the experimental group versus 36.8% in the control one (p < 0.05).
authors.forename: L A
authors.initials: LA
authors.lastname: Skvortsova
authors.forename: M V
authors.initials: MV
authors.lastname: Pavlova
authors.forename: T I
authors.initials: TI
authors.lastname: Vinogradova
authors.forename: L I
authors.initials: LI
authors.lastname: Archakova
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007375:Interleukin-1 / Q000008:administration & dosage / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000276:immunology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000995:Antitubercular Agents; D007375:Interleukin-1; D007376:Interleukin-2